StockNews.AI
MDXG
StockNews.AI
4 hrs

MIMEDX Announces Launch of EPIXPRESS®

1. MIMEDX launched EPIXPRESS, expanding its advanced wound care portfolio. 2. EPIXPRESS incorporates fenestrations for improved fluid movement. 3. The product targets hard-to-heal wounds like diabetic foot ulcers. 4. EPIXPRESS features a tri-layer configuration and enhances treatment effectiveness. 5. EPIXPRESS is listed on Medicare's Average Sales Price File.

5m saved
Insight
Article

FAQ

Why Bullish?

The launch of EPIXPRESS enhances product offerings and customer appeal, promoting potential sales growth. Previous launches of similar products have positively affected MDXG’s stock performance.

How important is it?

The introduction of EPIXPRESS is significant for MDXG, indicating ongoing innovation and responsiveness to market demands.

Why Long Term?

EPIXPRESS could strengthen MDXG's market position over time by addressing chronic wound care needs, leading to sustained growth. Historically, innovations have resulted in longer-term revenue increases.

Related Companies

AcelRx Pharmaceuticals, Inc. (ACRX)Aplisol (BLOX)Wound Management Technologies (WMGT)
Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products October 06, 2025 09:28 ET  | Source: MiMedx Group, Inc MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions. “I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRESS, our R&D team has built upon the fantastic attributes the market loves about EPIEFFECT by incorporating fenestrations to allow for fluid movement through the tissue. A hallmark of our success has been, and will continue to be, a commitment to market-driven innovation.” EPIXPRESS expands MIMEDX’s PURION®-processed placental allograft offering aimed at helping clinicians treat acute and chronic, hard-to-heal wounds. Like EPIEFFECT, EPIXPRESS is a lyophilized product, and features a thick, tri-layer configuration. Additionally, EPIXPRESS adds fenestrations to the sheet configurations to help with fluid movement. EPIXPRESS can be used on a wide range of common conditions, such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), and other wound types, including those where the need exists to secure the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds. About EPIXPRESSEPIXPRESS is a lyophilized human placental-based allograft that includes the amnion layer, intermediate layer, and chorion layer. EPIXPRESS is intended for use as a barrier to provide a protective environment in acute and chronic wounds. The product provides a biocompatible human Extracellular Matrix (ECM) and contains 300+ regulatory proteins. Additionally, like MIMEDX’s other Wound products, including EPIFIX®, EPICORD®, EPIEFFECT®, CELERA™ and EMERGE™, EPIXPRESS is listed on the Medicare Part B Average Sales Price File. To learn more, please visit https://www.mimedx.com/EPIXPRESS/. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact:Matt NotarianniInvestor Relations470-304-7291mnotarianni@mimedx.com

Related News